Because of the significant need and market size, as well as the elective nature of the procedure, Cardeon has identified cardiac surgery as its initial area of focus. Cardeon's patented systems are designed to provide physicians with an alternative platform of neuroprotection and, when needed, extend critical time to treat disease or injury.
Stroke ranks third in mortality, but is the leading cause of disability.
Within each of these, causes of morbidity and mortality is an associated loss of neurologic integrity, a significant contributor to the patient's demise. The Cardeon team includes a number of highly experienced medical device personnel with extensive industry experience. Cardeon is strongly committed to incorporating a scientific approach to addressing the challenges related to maintaining neurologic integrity and therefore relies heavily on its Scientific Advisory Board which includes clinical leaders from multiple specialties. The company is headquartered in Cupertino, California. This site is best viewed with MacroMedia Flash and at 800x600 resolution or higher.